How to buy Tarsus Pharmaceuticals stock (Tarsus Pharmaceuticals)

Tarsus Pharmaceuticals is a biotechnology business based in the US. Tarsus Pharmaceuticals shares (TARS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $54.04 – an increase of 3.92% over the previous week. Tarsus Pharmaceuticals employs 244 staff and has a trailing 12-month revenue of around $129.6 million.

Our top picks for where to buy Tarsus Pharmaceuticals Inc stock

Buy Tarsus Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Tarsus Pharmaceuticals stock price (NASDAQ: TARS)

Use our graph to track the performance of TARS stocks over time.

Tarsus Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$54.04
52-week range	$18.99 - $56.77
50-day moving average more info button	$46.93
200-day moving average more info button	$35.15
Wall St. target price	$65.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-3.75

Is it a good time to buy Tarsus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tarsus Pharmaceuticals price performance over time

Historical closes compared with the close of $54.04 from 2024-12-24

1 week (2024-12-20)	2.14%
1 month (2024-11-27)	6.29%
3 months (2024-09-26)	63.02%
6 months (2024-06-26)	113.94%

1 year (2023-12-26)	168.06%
2 years (2022-12-23)	272.43%
3 years (2021-12-23)	108.41%
5 years (2019-12-23)	N/A

Tarsus Pharmaceuticals financials

Revenue TTM	$129.6 million
Gross profit TTM	$-17,763,000
Return on assets TTM	-27.26%
Return on equity TTM	-59.56%
Profit margin	-103.64%
Book value	$6.22
Market Capitalization more info button	$2.1 billion

TTM: trailing 12 months

Tarsus Pharmaceuticals share dividends

We're not expecting Tarsus Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Tarsus Pharmaceuticals share price volatility

Over the last 12 months, Tarsus Pharmaceuticals's shares have ranged in value from as little as $18.99 up to $56.77. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tarsus Pharmaceuticals's is 1.004. This would suggest that Tarsus Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Tarsus Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Kala Pharmaceuticals (KALA.US): -2.142
• Kodiak Sciences (KOD.US): 2.251
• Regenxbio (RGNX.US): 1.232

Tarsus Pharmaceuticals overview

Tarsus Pharmaceuticals, Inc. , a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Frequently asked questions

What percentage of Tarsus Pharmaceuticals is owned by insiders or institutions?
Currently 8.73% of Tarsus Pharmaceuticals shares are held by insiders and 120.739% by institutions. How many people work for Tarsus Pharmaceuticals?
Latest data suggests 244 work at Tarsus Pharmaceuticals. When does the fiscal year end for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals's fiscal year ends in December. Where is Tarsus Pharmaceuticals based?
Tarsus Pharmaceuticals's address is: 15440 Laguna Canyon Road, Irvine, CA, United States, 92618 What is Tarsus Pharmaceuticals's ISIN number?
Tarsus Pharmaceuticals's international securities identification number is: US87650L1035